Diagnostic Electrocardiograph/ECG Market worth US$15.18 billion by 2032 with 7.4% CAGR
DELRAY BEACH, Fla., June 13, 2025 /PRNewswire/ -- The global Diagnostic Electrocardiograph/ECG Market, valued at US$8.59 billion in 2024 stood at US$9.19 billion in 2025 and is projected to advance at a resilient CAGR of 7.4% from 2025 to 2032, culminating in a forecasted valuation of US$15.18 billion by the end of the period. The growth in the ECG diagnostic market can be attributed to several critical factors. The rising prevalence of chronic conditions, particularly CVDs, is a significant driver. Additionally, there is a marked shift towards home healthcare solutions, propelled by advancements in wearable technology and the broader digital transformation within the healthcare sector. The burgeoning geriatric demographic, which is increasingly susceptible to cardiac disorders, further amplifies the demand for ECG diagnostics across various healthcare environments. Technological innovations, specifically the advent of portable ECG devices and AI-enhanced ECG interpretation, are enhancing diagnostic precision and improving patient accessibility. Moreover, government initiatives aimed at promoting cardiac health, coupled with a growing acceptance of point-of-care diagnostic methodologies, are anticipated to bolster market growth moving forward.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=173
Browse in-depth TOC on "Diagnostic Electrocardiograph/ECG Market"
150 - Tables60 - Figures250 - Pages
By Product, the diagnostic ECG market is categorized into diagnostic ECG devices and diagnostic ECG software & services, with the diagnostic ECG devices segment commanding the largest market share. This predominance is attributable to the critical role these devices play in routine cardiac diagnostics, the swift identification of arrhythmias, and long-term cardiac monitoring. Standard resting ECGs serve as fundamental assessments in both primary care and specialized medical environments, while Holter monitors facilitate extensive and continuous cardiac surveillance over extended periods. The demand for these diagnostic tools is significantly influenced by the rising geriatric population, which correlates with an increase in CVD prevalence within this demographic. According to WHO, over 80% of CVD-related fatalities result from heart attacks and strokes, with one-third of these deaths occurring prematurely in individuals under 70 years of age; this statistic underscores the urgent need for effective cardiac monitoring solutions in the face of growing cardiovascular health challenges.
By lead type, the diagnostic ECG market is categorized based on lead types into 12-lead, 5-lead, 3-lead, 6-lead, and single-lead ECG devices. Notably, 12-lead ECG systems dominate the market due to their superior diagnostic capabilities, allowing for precise measurement of cardiac electrical activity. Regarded as the gold standard for the advanced diagnosis of cardiac pathologies, including myocardial infarctions and arrhythmias, these systems are widely endorsed by clinical guidelines for use in hospitals and cardiology clinics. Their approval for emergency and critical care applications further cements their market leadership. Key manufacturers of 12-lead diagnostic ECG devices include Koninklijke Philips N.V. (Netherlands), ACS Diagnostics (US), OSI Systems, Inc. (US), and GE Healthcare (US).
By type, the diagnostic ECG market is further segmented into portable, wearable, and implantable ECG devices. In 2024, the portable ECG devices segment accounted for the largest market share, driven by their convenience, mobility, and diverse applications in both clinical settings and home care. Unlike traditional ECG machines, which are typically bulkier and stationary, portable devices enable on-demand or continuous cardiac monitoring from virtually any location. A significant advantage of these devices is their ability to wirelessly record and transmit ECG data to healthcare providers, facilitating remote patient monitoring. This capability not only allows for timely interventions but also minimizes the need for frequent hospital visits, which is particularly beneficial for patients with chronic heart conditions. As a result, the emphasis on remote patient care and the demand for personalized healthcare solutions are the primary factors propelling the growth of portable ECG devices, solidifying their dominant position within the diagnostic ECG market.
By end user, the diagnostic ECG market is segmented into hospitals, primary care centers, cardiac centers, ambulatory surgery centers, urgent care settings, and home care settings. The hospitals segment held the largest market share primarily due to the high volume of cardiovascular patient admissions and the presence of state-of-the-art diagnostic infrastructure. The integration of ECG systems with other cardiac diagnostic modalities enhances their utility in both inpatient and outpatient settings, especially within emergency and ICUs. The increasing rates of hospital admissions for cardiac conditions, combined with the emphasis on early detection and timely intervention, position hospitals as the predominant end users of ECG technologies; this trend is a key driver of overall market expansion in the diagnostic ECG market.
By geography, the diagnostic ECG market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The North American market has successfully secured a substantial share, driven by several key factors. One major contributor is the growth in the geriatric population, which is leading to an increased demand for healthcare services and diagnostic tools. Alongside this demographic shift, there has been a notable rise in the prevalence of chronic diseases, such as CVDs and diabetes, that require regular monitoring and management through advanced diagnostic ECG solutions. Additionally, the enhancement of healthcare infrastructure in the region plays a crucial role in facilitating better access to these diagnostic services. Hospitals & clinics are increasingly equipped with state-of-the-art technology and resources, enabling healthcare providers to offer timely and effective care. Furthermore, supportive government initiatives aimed at improving healthcare accessibility also have a positive impact on the market. Policies designed to reduce barriers to healthcare services and promote innovative diagnostic technologies are helping to ensure that patients can receive necessary care without significant obstacles. The strategic expansion of key players in the North American market, which includes both established companies and emerging startups, is anticipated to further bolster market growth. The active presence of these industry leaders not only enhances competition but also drives innovation in product development, ultimately benefiting patients and healthcare providers alike. Overall, these factors collectively signify a robust growth trajectory for the ECG diagnostic solutions market in North America.
Request Sample Pages : https://www.marketsandmarkets.com/requestsampleNew.asp?id=173
As of 2024, diagnostic ECG market was dominated by GE HealthCare (US), Koninklijke Philips N.V. (Netherlands), Baxter (US), FUKUDA DENSHI (Japan), Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (China), NIHON KOHDEN CORPORATION (Japan), OSI Systems, Inc. (US), Bittium (Finland), iRhythm Technologies, Inc. (US), Lepu Medical Technology (Beijing) Co., Ltd. (China), Midmark Corporation (US), BPL Medical Technologies (India), SCHILLER (Switzerland), ACS Diagnostics (US), Allengers (India), and Bionet Co., Ltd. (South Korea), among others.
GE Healthcare (US):
GE Healthcare is a well-established entity in the diagnostic ECG sector, boasting over 125 years of industry experience and a formidable reputation within the global healthcare landscape. The company effectively utilizes its extensive global footprint in medical technology, diagnostics, and digital solutions, catering to a diverse clientele across 160 countries while adhering to sustainable operational practices. Central to GE Healthcare's strategy is a robust emphasis on R&D to optimize existing offerings and innovate new products and services. This commitment allows the company to stay responsive to evolving customer demands and to capitalize on emerging market opportunities. In a notable move for 2024, GE Healthcare invested approximately USD 969 million to enhance manufacturing capabilities and local R&D initiatives in India over the next five years. The company's growth strategy encompasses a range of collaborations, agreements, expansions, and acquisitions to strengthen its operational reach and market presence. These strategic endeavors not only expand the product portfolio but also fortify the company's competitive standing in the market. In a recent development, GE Healthcare partnered with the Mayo Clinic in September 2023 to leverage advanced technologies and improve the precision of diagnostics and treatment processes for healthcare providers.
Koninklijke Philips N.V. (Netherlands)
Koninklijke Philips N.V. (Royal Philips) serves as the parent organization of the Philips Group, strategically operating across four core domains: Personal Health, Diagnosis & Treatment, Connected Care, and Others. Within the Connected Care segment, Philips provides advanced diagnostic solutions, including cardiographs, Holter monitoring systems, and stress-testing ECGs. The company's growth strategy is heavily centered on forming strategic partnerships in high-potential markets and fostering collaborative efforts to drive innovation. A notable example of this approach is the 2023 partnership with NYU Langone Health to leverage innovative technologies and enhance patient care over an eight-year span. Additionally, in January 2025, Philips is set to present its latest innovations at Arab Health 2025. These advancements emphasize the integration of smart systems, automation, and cloud-based informatics into healthcare delivery, targeting reductions in clinician workload and improvements in operational workflows, ultimately leading to enhanced patient outcomes. Key subsidiaries within the Philips ecosystem include Philips Oral Healthcare, LLC (US), Philips GmbH (Germany), Philips Ultrasound, Inc. (US), and Philips Consumer Lifestyle B.V. (Netherlands). The company maintains a comprehensive operational footprint across North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa.
Shenzhen Mindray Bio-Medical Electronics Co. (China)
Shenzhen Mindray Bio-Medical Electronics is a prominent entity in the diagnostic ECG segment, distinguished by its diverse operational structure across three primary business verticals: Patient Monitoring and Life Support, In-vitro Diagnostics, and Medical Imaging Systems. Within the Patient Monitoring & Life Support sector, the company delineates its offerings into Patient Monitoring Systems, ECG devices, and ancillary products. Mindray dedicates more than 10% of its revenue to R&D, which underpins its commitment to innovation and sustains a formidable portfolio of over 3,000 patents. This investment not only fuels technological advancement but also strengthens its competitive edge. The company has also established strategic partnerships to enhance its market penetration and product offerings. Notably, its collaboration with Amazon Business facilitates improved access to medical equipment for healthcare systems, hospitals, and practitioners, streamlining procurement and distribution channels in a rapidly evolving healthcare landscape.
For more information, Inquire Now!
Related Reports:
Cardiac Monitoring & Cardiac Rhythm Management Devices Market
Patient Monitoring Devices Market
Brain Monitoring Market
Patient Temperature Monitoring Market
MRI Systems Market
Get access to the latest updates on Diagnostic Electrocardiograph/ECG Companies and Diagnostic Electrocardiograph/ECG Market Size
About MarketsandMarkets™:
MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .
Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC.1615 South Congress Ave.Suite 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: sales@marketsandmarkets.comVisit Our Website: https://www.marketsandmarkets.com/
Logo: https://mma.prnewswire.com/media/1868219/MarketsandMarkets_Logo.jpg
View original content to download multimedia:https://www.prnewswire.com/news-releases/diagnostic-electrocardiographecg-market-worth-us15-18-billion-by-2032-with-7-4-cagr--marketsandmarkets-302480972.html
SOURCE MarketsandMarkets
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
12 minutes ago
- Business Insider
I invested $30,000 to scale my European-based tote bag business in the US — then tariffs hit
This as-told-to essay is based on a conversation with Catalina Mendoza, a 26-year-old cofounder of a luxury tote bag business based in Germany. The business's financials have been verified by Business Insider. The following has been edited for length and clarity. I'd always cringe when I saw people crying on social media. I never wanted to be one of them. But in April, my husband got off a call with our suppliers in China and told me we had to stop selling in the US immediately. Tariffs on US imports from China had jumped to 145%. We started hearing about tariffs earlier in the year, but we were caught up in the decision-making process and didn't act fast enough. Once they were in effect, I knew we had to inform our customers, so I made a TikTok video — and in it, I cried. It wasn't fake whatsoever. This whole experience has been upsetting and, honestly, frightening. We had no prior business experience My husband and I launched The Tote Library, a luxury tote bag business, in 2022. I was still an art student at the time, and while my husband had studied marketing, neither of us had much practical business experience. The idea was to turn my designs into something functional and cute. I made the first prototype, and we found a supplier in China on Taobao, a local online shopping platform, who could produce it. My husband used Google Translate to communicate with them. We launched with about five bags per design and started marketing them on social media. I began posting videos online using trending audio. Eventually, one video gained traction. It wasn't a viral sensation, but it got tens of thousands of views. We sold out immediately. Social media felt like the key to e-commerce. I kept posting and grew my account. Even though we were based in Europe, our biggest traction came from the US. The American market made up almost 50% of our total sales. Last year, we wanted to scale up. We dreamed of expanding beyond tote bags, launching other luxury items, and even homeware. We also focused heavily on growing our business in the US. Our ambition was to open a warehouse there so we could ship faster to our American customers. Over the next six months, we invested heavily in the US market, mainly through paid ads on Meta and other social media. We spent more than $32,000 on our US-based campaign. We also gifted more than 1,000 bags to creators in the US, covering the production and international shipping costs. It was a high-cost risk, but it felt worth taking. That was until the tariffs came into effect in April. Investing in US sales felt like a risk worth taking, then tariffs hit Almost overnight, our US sales dropped to zero because we had to remove the country from our Shopify store. Our luxury items already sit at the high end of the tote bag market, and increasing prices to cover the tariff rise wasn't an option. It was terrifying. We had worked so hard, and just as we were ready to grow, it felt like it had been snatched away in an instant. In May, a 90-day grace period temporarily reduced the tariffs. We decided to reopen sales to the US, but the shift probably confused our customers. We don't know what happens after the grace period ends. It feels so unpredictable, and I already feel like our reputation in the US has taken a hit. While US sales are up and down, the TikTok video of me crying went viral, increasing brand awareness in Europe. Our main focus now is on European consumers. We plan to start producing locally and marketing more toward what people in Europe like. I'm even considering a rebrand catering to European tastes. I'm looking into moving production, potentially to Portugal. Producing in Portugal will likely make the bags more expensive, but I've learned that having supply chains closer to home means you have more control. It's been a major setback for our business I'm trying to remain positive about the future, but it feels like we're starting from scratch. The business is our only source of income. We're looking into whether we need side jobs to bring in some stability. I also have two people working with us on social media and marketing, and suddenly, I'm worried about making enough to cover payroll. We've become accustomed to a certain lifestyle, but we will undoubtedly need to cut back. I'm originally from Chile, and up until now, I've been able to visit home at least once a year. With all this instability, I'm not sure I can justify spending money on plane tickets or vacations anymore. Emotionally, it feels like a step back. Some days, it's hard to show up as the face of the company when I'm not feeling my best. I just try to remind myself that this isn't the end of the world. If I've learned one thing from this experience, it's that I can't rely on the US or a single market, especially in the current political climate.
Yahoo
7 hours ago
- Yahoo
Life Science Labs Signal Shifting Strategies Amid New Economic Pressures, According to Survey of 550+ Researchers
ARLINGTON, Va., June 13, 2025 /PRNewswire/ -- New survey insights reveal a measurable shift in how life science labs are responding to global financial uncertainty, rising operational costs, and upcoming U.S. tariff policies. Based on responses from more than 550 academic and industry researchers, the latest data from BioInformatics' Beyond the Bench series captures how lab priorities, purchasing decisions, and funding strategies have evolved from January to mid-April 2025—offering a rare pre- and post-policy view of market sentiment. While the first wave of the survey was fielded prior to the announcement of new tariff policies, the second wave offers a timely comparison as labs began adjusting to anticipated policy changes under the Trump administration and broader macroeconomic pressures, including inflation, tightened research budgets, and supply chain strain. Click here to download the Lab Budgets & Funding Survey Key Survey Findings Include: Funding confidence is declining, with only 57% of labs reporting confidence in securing 2025 funding—down from 66% in the first wave. Financial strain is hitting North American labs harder than those in Europe: 46% report new funding challenges (vs. 21% in Europe), and over half are considering personnel cuts, compared to just 28% in Europe. 42% of labs cite new concerns about securing funding through year-end, signaling heightened financial risk across the sector. Cost-saving strategies are accelerating, including resource sharing, supplier renegotiations, outsourcing, and delayed equipment purchases. These findings reflect shifting institutional priorities and underscore the growing need for timely, market-aligned planning as labs face increased constraints and financial pressure. "By fielding this survey before and after key policy announcements, we're able to offer a real-time snapshot of how labs are adjusting to economic volatility," said Richa Singh, VP, Market Insights at BioInformatics. "As tariff policies begin to reshape lab planning, companies need focused, evidence-backed insights to align their strategies. This data helps commercial teams track funding sentiment, adapt messaging, and make confident, evidence-based decisions—especially in a market where priorities can change within weeks." About Beyond the Bench Beyond the Bench is a free monthly intelligence series created by BioInformatics to help life science and diagnostics companies understand how customer sentiment and commercial priorities are shifting—particularly during times of uncertainty and industry disruption. Powered by the Science Advisory Board, BioInformatics' proprietary network of over 55,000 life science professionals, each report delivers survey-based insights on market trends, strategic shifts, and buyer behavior. The series was launched to provide a clear, unbiased view into the evolving challenges facing researchers and decision-makers—giving commercial teams actionable guidance to align strategy, messaging, and resource planning with what matters most to their customers. Access & Get Involved: Download the Lab Budgets & Funding Survey Sign up to receive monthly Beyond the Bench reports Join the Science Advisory Board — qualify to participate in surveys, earn rewards, and shape the future of scientific research. About BioInformatics BioInformatics, part of the Science and Medicine Group, is a leading market research and advisory firm serving the life science and diagnostic industries. The company delivers custom and syndicated research powered by a proprietary global panel of more than 55,000 professionals. View original content to download multimedia: SOURCE BioInformatics Inc.
Business Upturn
8 hours ago
- Business Upturn
Bombardier Completes Partial Redemption of US$500,000,000 of its 7.875% Senior Notes due 2027
By GlobeNewswire Published on June 14, 2025, 02:01 IST MONTRÉAL, June 13, 2025 (GLOBE NEWSWIRE) — Bombardier Inc. ('Bombardier') today announced that it has redeemed US$500 million principal amount of its outstanding 7.875% Senior Notes due 2027 (the 'Redemption Notes') as set forth in the notice of partial redemption issued May 14, 2025. Payment of the redemption price and surrender of the Redemption Notes for redemption are being made through the facilities of the Depository Trust Company in accordance with the applicable procedures of the Depository Trust Company. This press release does not constitute an offer to sell or buy or the solicitation of an offer to buy or sell any security and shall not constitute an offer, solicitation, sale or purchase of any securities in any jurisdiction in which such offering, solicitation, sale or purchase would be unlawful. The Redemption Notes mentioned herein have not been and will not be registered under the United States Securities Act of 1933, as amended, any state securities laws or the laws of any other jurisdiction, and may not be offered or sold in the United States absent registration or an applicable exemption from such registration requirements. The Redemption Notes mentioned herein have not been and will not be qualified for distribution to the public under applicable Canadian securities laws and, accordingly, any offer and sale of the securities in Canada may only be made on a basis which is exempt from the prospectus requirements of such securities laws. FORWARD-LOOKING STATEMENTS Certain statements in this announcement are forward-looking statements based on current expectations. By their nature, forward-looking statements require us to make assumptions and are subject to important known and unknown risks and uncertainties, which may cause our actual results in future periods to differ materially from those set forth in the forward-looking statements. For information Francis Richer de La FlècheVice President, Financial Planning and Investor RelationsBombardier +1 514 240 9649 Mark MasluchSenior Director, CommunicationsBombardier +1 514 855 7167 Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
